Ethomid Dosage/Direction for Use

Recommended Dose: Ethionamide is administered orally without regard to meals. Ethionamide usually is administered once daily, but may be given in divided doses if GI intolerance occurs. If ethionamide is given as a single daily dose, it should be given at the time of day that the patient find most suitable in order to avoid or minimize GI intolerance.
Adult dosage: For use in conjunction with other antituberculosis agents for the treatment of active tuberculosis in adults, the usual dosage of ethionamide is 15-20 mg/kg daily. The recommended initial dosage is 250 mg daily, with gradual titration to optimal dosage based on patient tolerance (Maximum dose: 1 g/day).
Pediatric dosage: The optimum pediatric dosage has not been established, but dosages of 10-20 mg/kg daily given in 2 or 3 divided doses after meals or 15 mg/kg once daily have been recommended for children.
Hepatic impairment: Ethionamide is almost completely metabolised in the liver. Its use should be avoided in patients with severe hepatic impairment and should be used with caution in patients with less severe hepatic impairment.
Renal impairment: Although some clinicians state that dosage adjustments are not necessary in patients with renal impairment, others state that ethionamide dosage should be reduced to 250-500 mg daily in patients with creatinine clearance less than 30 mL/minute and in those undergoing hemodialysis.
Duration of therapy: Therapy for tuberculosis should be continued long enough to prevent relapse. The minimum duration of treatment currently recommended for patients with culture-positive pulmonary tuberculosis is 6 months (26 weeks) and recommended regimens consist of an initial intensive phase (2 months) and a continuation phase (usually either 4 or 7 months). Duration of treatment should be based on individual clinical response. In general, continue therapy until bacteriological conversion has become permanent and maximal clinical improvement has occurred.
Mode of Administration: Orally.